The Mortgage Market Review (MMR) could significantly affect the protection market, Swiss Re has said.
Aviva's leap up the blue-chip index has ignited further market speculation that at least two insurers could be mulling over a possible approach worth 575p a share valuing the insurer at £14.8bn.
Surgeons' representatives have questioned Bupa's claim of support by the General Medical Council (GMC) for its knee surgery review procedure.
Aviva has unveiled a product allowing grandparents the chance to buy specialist health insurance for their grandchildren.
IFAs could have help with the paperwork from their local MP as part of a scheme to make law makers better understand the realities of running a small company.
Directors of IFA firms want to be compassionate employers, but there is always the risk of being taken for a sap by employees who feel unappreciated.
Nucleus has stopped trading six Castlestone funds on the platform following an FSA visit to the asset management's premises this week.
Hector Sants is encouraging Arch cru investors to take the FSA-brokered 70% payment deal and has warned against attempts to get a better return through the Financial Ombudsman or the courts.
Axa has added Barnett Waddingham's SIPP to its Elevate platform.